Genmab and AbbVie secure EU approval for Tepkinly in relapsed follicular lymphoma
Discover how Tepkinly’s EU approval could reshape second-line follicular lymphoma treatment and the safety and access questions still ahead.
Discover how Tepkinly’s EU approval could reshape second-line follicular lymphoma treatment and the safety and access questions still ahead.
Find out how Genmab’s epcoritamab data could reshape elderly DLBCL treatment as bispecific antibodies move into frontline care.